Last €78.43 EUR
Change Today +0.316 / 0.40%
Volume 877.9K
As of 3:45 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MRK) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - €80.93
52 Week Low
04/15/14 - €56.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK KGAA (MRK)

Related News

No related news articles were found.

merck kgaa (MRK) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MRK) Details

Merck KGaA, together with its subsidiaries, discovers, develops, manufactures, and markets products in the pharmaceutical and chemical sectors worldwide. It operates through four divisions: Merck Serono, Consumer Health, Performance Materials, and Merck Millipore. The Merck Serono division provides prescription medicines for the treatment of cancer, multiple sclerosis, infertility, growth disorders, cardiovascular, and metabolic diseases and allergies. The Consumer Health division offers over-the-counter pharmaceuticals for mobility and agility, everyday health protection, women’s and children’s health, and cough and cold under the Bion 3, Nasivin, Femibion, Seven Seas, Sangobion, Cebion, Sedalmerck, and Kytta brand names. The Performance Materials division provides specialty chemicals for use in various end products, such as liquid crystals for displays; LED materials for lighting, and OLED materials for lighting and displays; functional materials for solar panels and energy solutions; pigments, active ingredients, and fillers for cosmetics, food, and pharmaceutical products; and pigments and functional materials for coatings, printing, and plastics. The Merck Millipore division offers tools and laboratory chemicals that are used in the research, pharmaceutical and biotechnology industries, and analytical and clinical laboratories. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

39,355 Employees
Last Reported Date: 11/13/14
Founded in 1668

merck kgaa (MRK) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €5.4M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
Member of Executive Board and Chief Executive...
Total Annual Compensation: €4.5M
General Partner and Member of Executive Board
Total Annual Compensation: €3.7M
Compensation as of Fiscal Year 2013.

merck kgaa (MRK) Key Developments

Pfizer Forms Global Strategic Alliance with Merck KGaA to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

Pfizer Inc. announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of cancer. Pfizer and Merck KGaA will explore the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with Pfizer's and Merck KGaA's broad portfolio of approved and investigational oncology therapies. Building on the ongoing Phase 1 program that has treated more than 550 patients, both companies will collaborate on up to 20 high priority immuno-oncology clinical development programs expected to commence in 2015. These clinical development programs include up to six trials (Phase 2 or 3) that could be pivotal for potential product registrations. There are currently two clinical development programs underway evaluating Merck KGaA's anti-PD-L1 antibody. In a Phase 1 trial, more than 550 patients have been treated with MSB0010718C across multiple types of cancers. Separate from the PD-L1 programs, Pfizer and Merck KGaA will also combine resources and expertise to advance Pfizer's anti-PD-1 antibody into Phase 1 trials. The parties have also agreed to co-promote Pfizer's XALKORI in the United States and several other key markets. Under the terms of the agreement, Merck KGaA will receive an upfront payment of $850 million and is eligible to receive regulatory and commercial milestone payments up to approximately $2 billion. Both companies will jointly fund all development and commercialization costs and all revenues obtained from selling any anti-PD-L1 or anti-PD-1 products generated from this collaboration will be shared equally.

Merck KGaA - Shareholder/Analyst Call

To discuss global strategic alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

Merck KGaA Reports Earnings Results for the Third Quarter of 2014; Revises Earnings Guidance for the Year 2014

Merck KGaA reported earnings results for the third quarter of 2014. For the quarter, the company reported earnings before interest, tax, depreciation, amortisation (EBITDA) and one-offs advanced 3.1% to EUR 857 million, despite the steep decline in royalty, licence and commission income. Net profit fell 27% to EUR 249 million. The earnings per share pre is stable at a level of EUR 1.15, owing to a higher D&A from the project of stop of tecemotide and a slight deterioration of the financial result. The company revised sales guidance for the year 2014. For the year, the company now expected sales to stand at up to EUR 11.2 billion (USD 13.94 billion) compared with an earlier forecast for EUR 10.9 billion to EUR 11.1 billion. EBITDA pre between EUR 3.3 billion and EUR 3.4 billion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:GR €78.43 EUR +0.316

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Koninklijke DSM NV €50.27 EUR +0.23
PPG Industries Inc $227.90 USD +0.89
Seiko Epson Corp ¥5,160 JPY -260.00
Solvay SA €109.30 EUR +2.30
Sherwin-Williams Co/The $260.07 USD +2.96
View Industry Companies

Industry Analysis


Industry Average

Valuation MRK Industry Range
Price/Earnings 28.6x
Price/Sales 3.0x
Price/Book 2.8x
Price/Cash Flow 5.0x
TEV/Sales 0.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at